- Supply TypeManufacturer, Exporter, Supplier, Retailer
- Preferred Buyer Location All over the world
LUCENTIS® (ranibizumab injection) is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.
Member Since 17 Years
Nature of Business Retailer
For Buyer 
For Seller 
Help 
Yusuf Sarai, Delhi